Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | PNMT | P11086 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 4/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | XIAP | P98170 | 1/20 | 0.37 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14046191 | 0.94 | HRH3 (0.48) | HRH3PNMTDRD2DRD3DRD1 | |
| SCHEMBL25814865 | 0.90 | DRD2 (0.51) | HRH3PNMTDRD2DRD1ACACB | |
| SCHEMBL14046130 | 0.86 | NPSR1 (0.40) | HRH3DRD2DRD3ACACB | |
| SCHEMBL14027774 | 0.86 | CARM1 (0.45) | HRH3DRD2DRD3ACACBCARM1 | |
| SCHEMBL20910014 | 0.83 | ALDH1A1 (0.44) | DRD2DRD3ACACBCARM1MEN1 | |
| SCHEMBL21266992 | 0.83 | ASIC3 (0.44) | DRD2DRD3ASIC3ACACBCARM1 | |
| SCHEMBL20883929 | 0.82 | HRH3 (0.46) | HRH3DRD2DRD1ACACB | |
| SCHEMBL20883616 | 0.82 | MAP3K5 (0.41) | DRD2DRD3DRD1ACACBCARM1 | |
| SCHEMBL22543653 | 0.82 | MAOB (0.44) | DRD2DRD3ACACBCARM1MEN1 | |
| SCHEMBL15756199 | 0.81 | OPRD1 (0.47) | ACACBMEN1KMT2AXIAPBIRC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827662-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827662-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230250080-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2023-08-10 | — | — | US | disclosed |
| WO-2023087027-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20230002407-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2023-01-05 | — | — | US | disclosed |
| EP-3896064-A1 | 4,6-DIAMINO-QUINOLINE-3-CARBONITRILE DERIVATIVES AS CANCER OSAKA THYROID (COT) MODULATORS FOR TREATING CROHN'S DISEASE AND ULCERATIVE COLITIS | Gilead Sciences, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| US-11066414-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| EP-3456717-B1 | 4,6-DIAMINO-QUINOLINE-3-CARBONITRILE DERIVATIVE AS CANCER OSAKA THYROID (COT) MODULATOR FOR TREATING INFLAMMATORY DISEASE | GILEAD SCIENCES INC (US) | 2021-03-17 | — | — | EP | disclosed |
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
| US-20200123172-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2020-04-23 | — | — | US | disclosed |
| US-20190248807-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2019-08-15 | — | — | US | disclosed |
| EP-3456717-A1 | TABLETS CONTAINING 4,6-DIAMINO-QUINOLINE-3-CARBONITRILE DERIVATIVES AS CANCER OSAKA THYROID (COT) MODULATORS FOR TREATING CANCER | GILEAD SCIENCES, INC. (US) | 2019-03-20 | — | — | EP | disclosed |
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2018-07-05 | — | — | US | disclosed |
| US-9878995-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170152240-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-06-01 | — | — | US | disclosed |
| US-20170008905-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
| WO-2008100423-A1 | GUT MICROSOMAL TRIGLYCERIDE TRANSPORT PROTEIN INHIBITORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250080-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | HRH3 442/4885PNMT 2670/4885DRD2 4189/4885 |
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | HRH3 3039/4885PNMT 1994/4885DRD2 4268/4885 |
| US-20230002407-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | HRH3 2884/4885PNMT 476/4885DRD2 4763/4885 |
| US-20200123172-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | HRH3 2884/4885PNMT 476/4885DRD2 4763/4885 |
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | HRH3 4580/4885PNMT 2059/4885DRD2 4745/4885 |
| US-20190248807-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | HRH3 2884/4885PNMT 476/4885DRD2 4763/4885 |
| US-20170152240-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | HRH3 2884/4885PNMT 476/4885DRD2 4763/4885 |
| US-11066414-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | HRH3 2884/4885PNMT 476/4885DRD2 4763/4885 |
| US-20170008905-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | HRH3 2884/4885PNMT 476/4885DRD2 4763/4885 |
| US-11827662-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | HRH3 2884/4885PNMT 476/4885DRD2 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.